Cytodyn, Inc.
Clinical trials sponsored by Cytodyn, Inc., explained in plain language.
-
New hope for HIV patients: experimental drug shows promise in small trial
Disease control CompletedThis study tested an experimental drug called PRO 140 in 6 adults with HIV whose current medications were no longer controlling the virus. The goal was to see if adding PRO 140 could lower the amount of HIV in their blood. The trial lasted 25 weeks and combined PRO 140 with other…
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated May 17, 2026 00:17 UTC
-
New weekly shot could replace daily HIV pills for some patients
Disease control CompletedThis study tested whether a weekly injection of PRO 140 could keep HIV under control in people whose virus was already suppressed by standard daily pills. Over 500 adults with a specific type of HIV (CCR5-tropic) switched from their usual combination therapy to PRO 140 alone for …
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated May 17, 2026 00:16 UTC
-
New drug targets hard-to-treat cancers in small study
Disease control CompletedThis study tested a drug called leronlimab in 16 adults with advanced solid tumors that have a specific protein (CCR5+). The main goals were to check safety and see if the drug could slow tumor growth. Participants had already tried other treatments or had no standard options lef…
Phase: PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Experimental drug leronlimab tested in severe COVID-19 patients
Disease control CompletedThis study tested a drug called leronlimab in 484 hospitalized adults with severe or critical COVID-19. The goal was to see if weekly injections could reduce deaths and improve recovery. The trial is now complete, and results help understand whether this treatment is safe and eff…
Phase: PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated May 08, 2026 12:03 UTC